Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Oncogenic potential of BRAF versus RAS.

Cancer letters - 18 Mar 2008

Benjamin Cara L, Ananthaswamy Honnavara N

Abstract excerpt

Mutations in the ERK pathway occur in approximately one-third of all human cancers and most often involve production of mutant RAS or BRAF. Several studies, including our own, have shown that mutations in the BRAF and RAS genes are generally mutually exclusive. This study was performed to determine the relative oncogenic potential of the BRAF and RAS oncogenes. BRAF(V600E)-, H-RAS(G12V)-, and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Neoplasms, Experimental
Share to Proto-Oncogene Proteins B-raf
Share to Mice, Nude

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Blotting, Western

Share to Cell Transformation, Neoplastic

Share to Fibroblasts

Share to Genes, p53

Share to Genes, ras

Source

Identifiers

PMID: 18280030
DOI: 10.1016/j.canlet.2007.10.033

Genes

BRAF

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Oncogenic potential of BRAF versus RAS.PMID 18280030Read ↗

Oncogene-induced senescence underlies the mutual exclusive nature of oncogenic KRAS and BRAF.Semantic proximity Read ↗

BRAFV600E: implications for carcinogenesis and molecular therapy.Semantic proximity Read ↗

The intermediate-activity (L597V)BRAF mutant acts as an epistatic modifier of oncogenic RAS by enhancing signaling through the RAF/MEK/ERK pathway.Semantic proximity Read ↗

K-ras Asp12 mutant neither interacts with Raf, nor signals through Erk and is less tumorigenic than K-ras Val12.Semantic proximity Read ↗

BRAF vs RAS oncogenes: are mutations of the same pathway equal? Differential signalling and therapeutic implications.Semantic proximity Read ↗

BRAF and RAS mutations in human lung cancer and melanoma.Semantic proximity Read ↗

Signaling pathways in Ras-mediated tumorigenicity and metastasis.Semantic proximity Read ↗

Differential contribution for ERK1 and ERK2 kinases in BRAFV600E-triggered phenotypes in adult mouse models.Semantic proximity Read ↗

What makes oncogenes mutually exclusive?Semantic proximity Read ↗

C-Raf inhibits MAPK activation and transformation by B-Raf(V600E).Semantic proximity Read ↗

Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation.Semantic proximity Read ↗

ERK1 and ERK2 mitogen-activated protein kinases affect Ras-dependent cell signaling differentially.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.